IBRX Q2 2023 Earnings — ImmunityBio, Inc. Revenue & Financial Results | Market Cap Arena

IBRXImmunityBio, Inc.

$8B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$41,000+17.1% YoY

Gross Profit

$41,000100.0% margin

Operating Income

-$85M-207670.7% margin

Net Income

-$138M-336290.2% margin

EPS (Diluted)

$-0.32

QoQ Revenue Growth

-88.6%

Cash Flow

Operating Cash Flow

-$80M

Free Cash Flow

-$88M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$291M

Total Liabilities

$936M

Stockholders' Equity

-$642M

Cash & Equivalents

$44M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$41,000	$35,000	+17.1%
Gross Profit	$41,000	-$6M	+100.7%
Operating Income	-$85M	-$80M	-6.9%
Net Income	-$138M	-$95M	-45.8%